References
- Dougados M, Baeten D. Spondyloarthritis. Lancet (London, England) [Internet]. 2011 Jun 18 [cited 2017 May 3];377(9783):2127–2137. Available at http://linkinghub.elsevier.com/retrieve/pii/S0140673611600718
- Stolwijk C, van Onna M, Boonen A, et al. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken) [Internet]. 2016 Sep [cited 2017 May 3];68(9):1320–1331. Available at http://doi.wiley.com/10.1002/acr.22831
- Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of Spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis [Internet]. 2009 Jun 1 [cited 2017 May 3];68(6):777–783. Available at http://ard.bmj.com/cgi/doi/10.1136/ard.2009.108233
- Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of Spondyloarthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis [Internet]. 2011 Jan [cited 2017 May 3];70(1):25–31. Available at http://www.ncbi.nlm.nih.gov/pubmed/21109520
- Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein. Rheumatology (Oxford) [Internet]. 2010 Mar 1 [cited 2017 May 3];49(3):536–541. Available at: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kep393
- Wanders A, van der Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum [Internet]. 2005 Jun [cited 2017 May 3];52(6):1756–1765. Available at http://www.ncbi.nlm.nih.gov/pubmed/15934081
- Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis [Internet]. 2016 Aug [cited 2017 May 3];75(8):1438–1443. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-207897
- Kroon F, Landewe R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623–1629.
- Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis [Internet]. 2012 Oct [cited 2017 May 3];71(10):1616–1622. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2011-201252
- van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum [Internet]. 2006;54(7):2136–2146. Available at http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L44051069%5Cnhttp://dx.doi.org/10.1002/art.21913%5Cnhttp://elvis.ubvu.vu.nl:9003/vulink?sid=EMBASE&issn=00043591&id=doi:10.1002/art.21913&atitle=Efficacy+and+safety+of+adalimumab+in+
- Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–3236.
- van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–591.
- Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–2517.
- Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70(5):799–804.
- Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091–2102.
- Sieper J, van der Heijde D, Dougados M, et al. THU0238 a randomized, double-blind, placebo-controlled, 16-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Ann Rheum Dis. 2015;74(Suppl 2):283.1–283.
- Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open [Internet]. 2017 Jan 27 [cited 2018 Feb 22];3(1):e000396. Available at http://www.ncbi.nlm.nih.gov/pubmed/28176964
- van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis [Internet]. 2017 Jun [cited 2017 Sep 18];76(6):978–991. Available at http://www.ncbi.nlm.nih.gov/pubmed/28087505
- Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282–298.
- Hamilton L, Barkham N, Bhalla A, et al. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics. Rheumatology [Internet]. 2017 Feb 1 [cited 2018 Feb 8];56(2):313–316. Available at https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kew223
- TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis | Guidance and guidelines | NICE. [cited 2018 Feb 8]. Available from: https://www.nice.org.uk/guidance/ta383/chapter/1-recommendations
- van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum [Internet]. 2006 Jul [cited 2017 May 3];54(7):2136–2146. Available at http://www.ncbi.nlm.nih.gov/pubmed/16802350
- Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis [Internet]. 2013 Jun [cited 2017 May 3];72(6):815–822. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-201766
- Sieper J, van der Heijde D, Dougados M, et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis [Internet]. 2012 May [cited 2017 May 3];71(5):700–706. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2011-200358
- Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis [Internet]. 2014 Jan [cited 2017 May 3];73(1):39–47. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2013-204231
- van der Heijde D, Dougados M, Landewé R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology [Internet]. 2017 May 12 [cited 2017 Oct 2];56(9):1498–1509. Available at https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kex174
- Braun J, Baraliakos X, Hermann K-G, et al. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open [Internet]. 2017 Apr 24 [cited 2017 Oct 2];3(1):e000430. Available at http://www.ncbi.nlm.nih.gov/pubmed/28848654
- Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis [Internet]. 2005;64(11):1557–1562. Available at http://www.ncbi.nlm.nih.gov/pubmed/15843448%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1755272
- Song I-H, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis [Internet]. 2011 Apr 1 [cited 2017 May 3];70(4):590–596. Available at http://ard.bmj.com/cgi/doi/10.1136/ard.2010.139667
- Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther [Internet]. 2013 [cited 2017 May 3];15(3):R67. Available at http://arthritis-research.biomedcentral.com/articles/10.1186/ar4244
- Dougados M, van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (Hoboken, NJ) [Internet]. 2014 Aug [cited 2017 Sep 18];66(8):2091–2102. Available at http://www.ncbi.nlm.nih.gov/pubmed/24891317
- van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum [Internet]. 2005 Feb [cited 2017 May 3];52(2):582–591. Available at http://doi.wiley.com/10.1002/art.20852
- Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology (Oxford) [Internet]. 2011 Sep 1 [cited 2017 May 3];50(9):1690–1699. Available at https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/ker194
- Inman RD, Davis JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum [Internet]. 2008 Nov [cited 2017 May 3];58(11):3402–3412. Available at http://www.ncbi.nlm.nih.gov/pubmed/18975305
- Sieper J, van der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol (Hoboken, NJ). 2015;67(10):2702–2712.
- Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med [Internet]. 2015;373(26):2534–2548. Available at http://www.nejm.org/doi/10.1056/NEJMoa1505066
- Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). WHO Expert Committee on Biological Standardization, Sixtieth report (19-23 October 2009). WHO Technical Report Series No. 977, 2013 - Annex 2. Accessed on 25 Aprill 25 2015, Available from: http://apps.who.int/medicinedocs/en/d/Js19941en/.
- Haustein R. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat. 2012;1(3):120–126.
- Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet (London, England) [Internet]. 2017 [cited 2017 Sep 18];389(10086):2304–2316. Available at http://www.ncbi.nlm.nih.gov/pubmed/28502609
- Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis [Internet]. 2016;13:annrheumdis-2015–208786. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-208786
- Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis [Internet]. 2016;annrheumdis-2015–208783. Available at http://ard.bmj.com/content/early/2016/04/28/annrheumdis-2015-208783
- Glintborg B, Kringelbach T, Høgdall E, et al. THU0123 non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease – impact on s-infliximab and antidrug-antibodies. Results from the National Danish Rheumatologic Biobank and the DANBIO registry. Ann Rheum Dis [Internet]. 2016 Jun 1 [cited 2017 Sep 18];75(Suppl 2):224–225. Available at http://ard.bmj.com/content/75/Suppl_2/224.2
- Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther [Internet]. 2015;15(12):1677–1683. Available at http://www.tandfonline.com.libgate.library.nuigalway.ie/doi/full/10.1517/14712598.2015.1103733#aHR0cDovL3d3dy50YW5kZm9ubGluZS5jb20ubGliZ2F0ZS5saWJyYXJ5Lm51aWdhbHdheS5pZS9kb2kvcGRmLzEwLjE1MTcvMTQ3MTI1OTguMjAxNS4xMTAzNzMzQEBAMA==
- Choe J-Y, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis [Internet]. 2017 Jan 1 [cited 2017 Sep 18];76(1):58–64. Available at http://www.ncbi.nlm.nih.gov/pubmed/26318384
- Benucci M, Gobbi FL, Bandinelli F, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res [Internet] cited. 2017 Sep 18; 65(1): 419–422. Available at https://link.springer.com/article/10.1007/s12026-016-8843-5
- Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis [Internet]. 2017 Jan [cited 2017 Sep 18];76(1):51–57. Available at http://www.ncbi.nlm.nih.gov/pubmed/26150601
- Lee YJ, Shin D, Kim Y, et al. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. Br J Clin Pharmacol [Internet]. 2016 Jul [cited 2017 Sep 18];82(1):64–73. Available at http://www.ncbi.nlm.nih.gov/pubmed/26972584
- von Richter O, Skerjanec A, Afonso M, et al. GP2015, a proposed etanercept biosimilar: pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes. Br J Clin Pharmacol [Internet]. 2017 Apr [cited 2017 Sep 18];83(4):732–741. Available at http://www.ncbi.nlm.nih.gov/pubmed/27790726
- Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis [Internet]. 2017 Oct [cited 2017 Sep 18];76(10):1679–1687. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-210459
- Weinblatt M, Baranauskaite A, Niebrzydowski J, et al. FRI0161 sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs continuation of the adalimumab reference product in patients with rheumatoid arthritis: result of phase III study. Ann Rheum Dis [Internet]. 2016 Jun 15 [cited 2018 Feb 8];75(Suppl 2):487.2–487. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2016-eular.1762
- January 2017 Position statement: biosimilar medicines. [cited 2018 Feb 8]; Available from: https://www.rheumatology.org.uk/Portals/0/Policy/PolicyStatements/Biosimilars.pdf
- Lord PAC, Farragher TM, Lunt M, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology(Oxford) [Internet]. 2010 Mar 1 [cited 2017 May 3];49(3):563–570. Available at https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kep422
- Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011 Jun 20;13(3):R94.
- Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis [Internet]. 2013 Jul [cited 2017 May 3];72(7):1149–1155. Available at: http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-201933
- Kristensen LE, Karlsson JA, Englund M, et al. Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish arthritis treatment group register. Arthritis Care & Res [Internet]. 2010 Oct 1 [cited 2017 Sep 18];62(10):1362–1369. Available at http://onlinelibrary.wiley.com/doi/10.1002/acr.20258/abstract
- Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36(4):801–808.
- Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(Basdai 50):665–670.
- Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis [Internet]. 2008;67(9):1276–1281. Available at http://www.ncbi.nlm.nih.gov/pubmed/18006539
- Lorenzin M, Ortolan A, Frallonardo P, et al. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord [Internet]. 2015;16:1–8. Available at http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4513706&tool=pmcentrez&rendertype=abstract
- Pedersen S.J., Zheng Z., Wichuk S., Chiowchanwisawakit P., Lambert R.G., Bernatsky S., Connor-Spady B., Spady D., Maksymowych W.P. Predictors of survival on the TNF-alpha inhibitor in an observational cohort of patients with ankylosing spondylitis: The role of MRI parameters of inflammation and structural damage. Presented at the 10th International Congress on Spondyloarthritides, 15–17 September 2016, Gent, Belgium (Poster 123).
- In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis - ACR Meeting Abstracts [Internet]. [cited 2017 Sep 18]; Available from: http://acrabstracts.org/abstract/in-contrast-to-men-women-with-nonradiographic-axial-spondyloarthritis-have-lower-response-rates-to-tnf-inhibitors-than-women-with-ankylosing-spondylitis/
- Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wiener Medizinische Wochenschrift. 2010;160(9–10):220–224.
- Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis [Internet]. 2011;70(1):157–163. Available at http://www.ncbi.nlm.nih.gov/pubmed/21062852
- Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor? Inhibitor therapy: results from the Danish nationwide DANBIO registry. Arthritis Rheum. 2013;65(5):1213–1223.
- Konttinen L, Tuompo R, Uusitalo T, et al. Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol. 2007;26(10):1693–1700.
- Sammaritano LR. Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat Clin Pract Rheumatol [Internet]. 2007;3(5):273–281. Available at http://www.ncbi.nlm.nih.gov/pubmed/17471246
- Pradeep DJ, Keat AC, Gaffney K, et al. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology [Internet]. 2008 Nov 1 [cited 2017 Sep 18];47(11):1726–1727. Available at: https://academic.oup.com/rheumatology/article/47/11/1726/1789402/Switching-anti-TNF-therapy-in-ankylosing
- Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four–week study. Arthritis Care & Res [Internet]. 2006 Oct 15 [cited 2017 Sep 18];55(5):812–816. Available at http://onlinelibrary.wiley.com/doi/10.1002/art.22236/full
- Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis [Internet]. 2007;66(10):1393–1397. Available at http://www.ncbi.nlm.nih.gov/pubmed/17613555%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1994295
- J. L. Rosales-Alexander, J. Balsalobre Aznar, S. Perez-Vicente, and C. Magro-Checa, Drug survival of anti-tumour necrosis factor alpha therapy in spondyloarthropathies: results from the Spanish emAR II Study. Rheumatology (Oxford), 2015 Aug:54:1459-1463.
- Coates LC, Cawkwell LS, Ng NWF, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology. 2008;47(6):897–900.
- Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005;64(10):1462–1466.
- Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005;64:229-234.
- van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–3070.
- van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–1331.
- Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis [Internet]. 2014;73(4):710–715. Available at http://www.ncbi.nlm.nih.gov/pubmed/23505240
- Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology. 2011;50(9):1690–1699.
- Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–2654.
- Machado P. Anti-tumor necrosis factor and new bone formation in ankylosing spondylitis: the controversy continues. Arthritis Rheum [Internet]. 2013;65(10):2537–2540. Available at http://www.ncbi.nlm.nih.gov/pubmed/23818040
- Maas F, Arends S, Brouwer E, et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken) [Internet]. 2017 Jul 1 [cited 2017 Sep 18];69(7):1011–1019. Available at http://onlinelibrary.wiley.com/doi/10.1002/acr.23097/pdf
- Molnar C, Scherer A, Baraliakos X, et al. Clinical and epidemiological research TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis [Internet]. 2017;77:1–7. [cited 2017 Oct 2]. Available at http://ard.bmj.com/content/annrheumdis/early/2017/09/22/annrheumdis-2017-211544.full.pdf
- van der Heijde D, Baraliakos X, Hermann K-GA, et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis [Internet]. 2018 Jan 17 [cited 2018 Feb 22]; annrheumdis-2017–212377. Available at http://www.ncbi.nlm.nih.gov/pubmed/29343510
- Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis - ACR Meeting Abstracts [Internet]. [cited 2018 Feb 22]; Available from: http://acrabstracts.org/abstract/secukinumab-demonstrates-low-radiographic-progression-and-sustained-efficacy-through-4-years-in-patients-with-active-ankylosing-spondylitis/
- Tan AL, Marzo-Ortega H, O’Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis [Internet]. 2004 Sep [cited 2017 Sep 18];63(9):1041–1045. Available at http://www.ncbi.nlm.nih.gov/pubmed/15066864
- Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis [Internet]. 2005 [cited 2017 Sep 18];64:296–298. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755331/pdf/v064p00296.pdf
- Song I-H, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis [Internet]. 2011 Jun [cited 2017 Sep 18];70(6):1108–1110. Available at http://www.ncbi.nlm.nih.gov/pubmed/21415053
- Song I-H, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum [Internet]. 2010 May [cited 2017 Sep 18];62(5):1290–1297. Available at http://www.ncbi.nlm.nih.gov/pubmed/20461780
- Song I-H, Heldmann F, Rudwaleit M, et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis [Internet]. 2013 Feb [cited 2017 Sep 19];72(2):305–306. Available at http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-201926
- Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis [Internet]. 2014 Jan 1 [cited 2017 Sep 21];73(1):95–100. Available at http://www.ncbi.nlm.nih.gov/pubmed/23765873
- Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis [Internet]. 2013;72(9):1475–1480. Available at http://www.ncbi.nlm.nih.gov/pubmed/22984171
- Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460.
- van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. [cited 2017 Sep 21]; Available from: http://ard.bmj.com/content/annrheumdis/76/8/1340.full.pdf
- Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases on behalf of the task force on the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis [Internet]. 2017 [cited 2017 Oct 2];77(10):1–10. Available at http://ard.bmj.com/content/annrheumdis/early/2017/09/02/annrheumdis-2017-211937.full.pdf
- Giardina AR, Ferrante A, Ciccia F, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int [Internet]. 2010 Sep 23 [cited 2017 Oct 8];30(11):1437–1440. Available at http://link.springer.com/10.1007/s00296-009-1157-3
- Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum [Internet]. 2005 Aug [cited 2017 Sep 18];52(8):2447–2451. Available at http://www.ncbi.nlm.nih.gov/pubmed/16052578
- van Denderen JC, Visman IM, Nurmohamed MT, et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol [Internet]. 2014 Sep [cited 2017 Sep 18];41(9):1843–1848. Available at http://www.ncbi.nlm.nih.gov/pubmed/25086071
- Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis [Internet]. 2010 Jan 1 [cited 2017 Sep 18];69(1):226–229. Available at http://www.ncbi.nlm.nih.gov/pubmed/19465402
- Rudwaleit M, Rosenbaum JT, Landewé R, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken) [Internet]. 2016 Jun [cited 2017 Sep 18];68(6):838–844. Available at http://www.ncbi.nlm.nih.gov/pubmed/26815944
- Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol [Internet]. 2003 Apr 1 [cited 2017 Sep 18];121(4):437. Available at http://www.ncbi.nlm.nih.gov/pubmed/12695239
- Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis [Internet]. 2016 Mar 1 [cited 2017 Sep 18];75(3):499–510. Available at http://www.ncbi.nlm.nih.gov/pubmed/26644232
- Song I-H, Appel H, Haibel H, et al. New onset of Crohn’s disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol [Internet]. 2008 Mar 1 [cited 2017 Sep 18];35(3):532–536. Available at http://www.ncbi.nlm.nih.gov/pubmed/18203308
- Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl [Internet]. 2014 May [cited 2017 Sep 18];91:47–55. Available at http://www.ncbi.nlm.nih.gov/pubmed/24789000
- Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut [Internet]. 2012 Dec [cited 2017 Sep 18];61(12):1693–1700. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22595313